inspiration in luscii's world
Luscii closes partnership with OMRON Healthcare to accelerate international expansion

Joining forces supports hospitals in moving care towards the home

 

Luscii, the e-health application for remote monitoring once developed as part of FocusCura, continues as an independent company. Healthcare entrepreneur and FocusCura founder Daan Dohmen, has acquired the majority of the shares and formed a strategic partnership with Omron Healthcare, known among other things, as the largest manufacturer of blood pressure monitors in the world. Part of this cooperation includes an investment, with which Luscii can accelerate its development further in the coming years. Omron will also support launches in more European countries, as the two companies announced today.

Remote monitoring

With Luscii, chronically ill patients can be monitored remotely. Remote monitoring via the Luscii app, in combination with smart algorithms, warns the patient’s healthcare network in the event of a deteriorating health situation. Direct contact is then made with the doctor or nurse via the app. Through this method, hospital visits, diagnostics and admissions can be prevented.
Luscii was conceived by a team at FocusCura. They were given an office in Amsterdam and space to attract technical talent from all over the world. That focus paid off. Today, Luscii is in use in almost half of all the hospitals in the Netherlands and the concept is reimbursed by 94% of insurers. “This is just the beginning”, says Dohmen. “We are now active in the Netherlands, the Nordics and the UK, and we will continue until all chronic patients have access to remote monitoring in their own region”.

Omron Healthcare

The collaboration with Omron will accelerate that ambition. Omron’s blood pressure monitors are the most widely used in scientific studies worldwide. With more than 200 million monitors in use by patients and care professionals, the manufacturer is number 1 in the field of medical remote monitoring. Dohmen: “The connection with Omron immediately launches us in places where we can make a difference”. The two companies have been working together for some time, through, among other things, the connection of Omron equipment to the Luscii app for heart, lung and vascular measurements at home, and with the development of artificial intelligence (AI) that provides doctors, nurses and patients with treatment advice based on remote monitoring.
For Omron, the collaboration is logical, says André van Gils, CEO of the European-American branch of the Japanese company. “Luscii is an international leader in the movement to bring hospital care to the home. We will help to expand that position and use our network, technology and knowledge to aid healthcare providers in meeting the rising demand for care. This partnership supports our mission to offer everyone a fuller and richer life without any compromises”.

Breakthrough

In European countries, efforts have been made for some time to make e-health available for chronic patients in order to prevent hospital visits and admissions. Despite that, a breakthrough is yet to be achieved. However, Luscii is one of the first digital healthcare concepts capable of bridging the important barriers in implementation. For example, Luscii successfully managed to integrate with large electronic patient records and secured reimbursement from insurers for their concept. Scientific research showed that using Luscii for specific target groups, such as patients with COPD, heart failure and resistant hypertension, can reduce hospital costs significantly and make patients feel safer.

 

FocusCura

FocusCura will continu its activities in home care under CEO Raoul Zaal. Dohmen handed over the CEO’s baton to the former Booking.com and Essent director a year ago. Under Zaal’s management, the number of users of FocusCura innovations continued to grow and 2018 ended with a strong operating result. Dohmen remains involved as a consultant and shareholder of FocusCura. Just like Medux, known for it’s brands Medipoint and Harting-bank.